<a href="https://www.fiercebiotech.com/biotech/private-swiss-biotechs-scale-record-funding-peak-amid-slowdown-public-financing" hreflang="en">Private Swiss biotechs hit record funding amid slowdown in public financing</a>
Private biotech companies in Switzerland achieved a record funding total of 1.15 billion Swiss francs in 2025, driven primarily by a few key players, despite a decline in public funding for the sector. This increase highlights a growing disparity in funding levels among biotech firms, as many others struggled to secure investment.
The key insight for you is that private funding for Swiss biotechs has reached record levels, with a significant portion of this capital concentrated among a few companies like Windward Bio and GlycoEra. This suggests a potential investment opportunity in Swiss biotech firms, particularly those that successfully attract significant private funding, as they may be poised for growth and innovation in competitive areas such as autoimmune diseases and biologics.